title: [Psychopharmacological treatment and quality of life in obsessive compulsive disorder].
abstract: OBJECTIVE
  Obsessive compulsive disorder (OCD) is an illness that considerably influences the family, academic, occupational and social functioning of patients. In this study, we aimed to investigate the impact of psychopharmacological treatment on quality of life in patients with OCD.
  
  
  METHODS
  Using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HDRS) and the World Health Organization Quality of Life Measurement Instrument Short Form, Turkish Version (WHOQOL-Bref TR) we assessed 53 patients who met the DSM-IV criteria for OCD to establish baseline values. The patients were consecutively assigned to receive either sertraline (100-200 mg/day), fluvoxamine (200-300 mg/day) or paroxetine (40-80 mg/day). We reassessed 36 (68%) of the initial group after 12 weeks.
  
  
  RESULTS
  The scores of obsession, compulsion and depression severity at follow-up were significantly lower than those of baseline scores. There is no significant difference between the pre and post-treatment quality of life domain scores. While psychological health scores at follow-up was significantly associated with baseline HDRS scores (r=-0.35, p<0.05), social relationship scores at follow-up was significantly associated with baseline social relationship scores (r=0.63, p<0.001) and compulsion scores (r=-0.37, p<0.05). Regression analyses revealed that social relationship scores at follow-up was associated with baseline compulsion severity whereas other follow-up quality of life domain scores were not predicted by any baseline variable.
  
  
  CONCLUSIONS
  Clinical viewpoint and objective evaluations should be essential in the evaluation of treatment outcome, and quality of life researches may be important complement to clinical researches.
authors.affiliation: Yüzüncü Yil U Tip Fak., Psikiyatri Bl., Van. lbesiroglu@yyu.edu.tr
authors.forename: Lütfullah
authors.initials: L
authors.lastname: Beşiroğlu
authors.forename: Faruk
authors.initials: F
authors.lastname: Uğuz
authors.forename: Ertan
authors.initials: E
authors.lastname: Yilmaz
authors.forename: Mehmet Yücel
authors.initials: MY
authors.lastname: Ağargün
authors.forename: Rüstem
authors.initials: R
authors.lastname: Aşkin
authors.forename: Adem
authors.initials: A
authors.lastname: Aydin
mesh_terms: D000328:Adult; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology*; D017374:Paroxetine / Q000008:administration & dosage / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020280:Sertraline / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016666:Fluvoxamine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline